As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their ...
Insulet has appointed Cristal Downing as chief corporate affairs officer, effective Monday, December 8. Downing will report to Ashley McEvoy, president and CEO at Insulet, a medical device company ...
The US FDA has cleared the first updates to the algorithm of the Omnipod 5 automated insulin delivery (AID) system (Insulet ...
The FDA cleared an updated algorithm for a hybrid closed-loop insulin delivery system that permits users to set a lower ...
Medical Device Network on MSN
FDA clears Insulet’s Omnipod 5 algorithm enhancements
Insulet anticipates that the Omnipod 5 algorithm update will launch in the US in H1 2026. The company highlighted that the ...
Zacks Investment Research on MSN
PODD stock benefits from FDA approval of Omnipod 5's enhancements
Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...
PODS pioneered portable moving and storage in 1998, offering a simpler and more flexible way to move for more than 25 years. Today, with over seven million moves, PODS provides residential and ...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
Toymaker Mattel has launched its latest addition to the Barbie range of dolls, the first with type 1 diabetes, which comes complete with a wearable continuous glucose monitor (CGM) and insulin pump.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback